Staphylococcus haemolyticus: Difference between revisions

From MicrobeWiki, the student-edited microbiology resource
Line 56: Line 56:


==Pathology==
==Pathology==
How does this organism cause disease?  Human, animal, plant hosts?  Virulence factors, as well as patient symptoms.
Staphylococci in general cause disease through their ability to spread widely in tissues ad their production of extracellular substances (Brooks,Butel and Morse, 2001). One example of such substances is coagulase, an enzyme-like protein produced by ''S.aureus'' that may deposit fibrin on the surface of the bacteria, altering their ingestion and destruction by phagocytic cells (Brooks,Butel and Morse, 2001).
 
Traditionally, production of coagulase is considered to represent the invasive pathogenic potential among staphylococci. (Brooks,Butel and Morse, 2001) ''S.haemolyticus'', however, is a coagulase-negative species. Therefore, like other non-aureus staphylococci, its pathogenic characters were not well-studied until recently, as ''S.haemolyticus'' is emerging to be a major cause of nosocomial infections (infections acquired during treatment at a hospital for another disease). Reported cases of infections caused by ''S.haemolyticus'' include septicemia (dysfunction of organ systems resulting from immune response to a severe infection), peritonitis (inflammation of the serous membrane lining abdominal cavity), and infections of urinary tract, wound, bone and joints. (Tristan,Lina, et al, 2006) In rare cases, ''S.haemolyticus'' has also been reported to cause infective endocarditis, inflammation of the inner of the heart (the endocardium), which might lead to severe complications such as heart failure or death. (Falcone,Campanile, et al, 2007) Common clinical symptoms of ''S.haemolyticus'' are fever and an increase in white blood cell population (leukocytosis) (Falcone,Campanile, et al, 2007).
 
Being the most common pathogen among staphylococci, virulent factors of ''S.aureus'' have been well-known. Important among them are different classes of enterotoxin (toxins released in lower-intestine, causing food poisoning), toxic shock syndrome toxin, and hemolysin (substances allow the bacteria to break down red-blood cells) (Novick, 2006). Some of these substances used to be considered to belong exclusively to ''S.aureus'', but are now discovered in the other non-aureus, coagulast-negative staphylococci as well (Tristan,Lina, et al, 2006). In one studies published in 1994, all strains of ''S.haemolyticus'' under investigation produced hemolysins in vitro (Molnar,Hevessy, et al, 1994). Investigators therefore suggested that hemolysins might be the important factor responsible for the high virulence of this staphylococcus species.
 
''S.haemolyticus''’ GGI are related in function and some properties to other relative staphylococci virulent factor, such as delta-lysin in S.aureus and SLUSH (''Staphylococcus lugdunensis synergistic hemolysin'') in ''S.lugdunensis'', the latter of which shows significant similarities in structure with GGI. (Tristan,Lina, et al, 2006) These findings suggest a connection between pathogenesis pathways and virulent factors of common staphylococcal pathogens.


==Application to Biotechnology==
==Application to Biotechnology==

Revision as of 02:20, 4 June 2007

A Microbial Biorealm page on the genus Staphylococcus haemolyticus

Classification

Higher order taxa

Bacteria; Firmicutes; Bacilli; Bacillales; Staphylococcaceae; Staphylococcus

Species

NCBI: Taxonomy

Staphylococcus haemolyticus

Description and significance

Staphylococus haemolyticus is a coagulase-negative member of the genus Staphylococcus. The bacteria can be found on normal human skin flora and can be isolated from axillae, perineum, and ingunial areas of humans. S.haemolyticus is also the second most common coagulase-negative staphylocci presenting in human blood. (Tristan,Lina, et al, 2006)

Lacking coagulase, an enzyme-like protein that was traditionally associated with virulent potential of staphylococci, coagulase-negative staphylococci are usually considered low-virulent pathogens comparing to the well-known pathogenic coagulase-positive Staphylococcus aureus. However, recent studies indicate that coagulase-negative staphylococci have emerged as a major cause of infection (Falcone,Campanile, et al, 2007). Staphylococcus haemolyticus itself is also a remarkable opportunistic baterial pathogen that is well-known for its highly antibiotic-resistant phenotype (Takeuchi,Watanabe, et al, 2005). The bacteria can cause meningitis, skin or soft tissue infections, prosthetic join infections, or bacteremia (Falcone,Campanile, et al, 2007). The ability of the bacteria to simultaneously resist against multiple types of antibiotic has been observed and studied for a long time. (Falcone,Campanile, et al, 2007) Common antibiotics that are subject to resistance in S haemolyticus include methicillin, gentamycin, erythormycin, and uniquely among staphylococci, glycopeptide antibiotics (Falcone,Campanile, et al, 2007). The resistance genes for each type of anitbiotic can be located on the chromosome (methicillin), on the plasmids (erythromycin) or on both chromosome and plasmids (gentamycin) (Froggatt,Johnston, et al, 1989).

In order to study the multi-drug resistant ability of Staphylococcus haemolyticus and its pathogenic characters, researchers sequenced the whole genome of one strain, JCSC1435 (Takeuchi,Watanabe, et al, 2005). Beside the bacteria’s antibiotic resistance genes, the study of the sequence also revealed a surprising number of homologous insertion sequences (ISs). These sequences might be responsible for the frequent genomic arrangement observed in this organism.(Froggatt,Johnston, et al, 1989)

Genome structure

(Takeuchi,Watanabe, et al, 2005)

The genome of Staphylococcus haemolyticus (strain JCSC1435) includes a circular chromosome of 2,685,015 bp and 3 plasmids of 2,300 bp, 2,366 bp and 8,180 bp.

Comparative genomic analysis has revealed significant similarities between the genomes of S.haemolyticus and those of the other two well-known staphylococci, S.aureus and S.epidermis. Beside the comparable genome sizes, a large proportion of open reading frames (orfs) are conserved both in the sequences and in their order on the chromosome. However, the study also found a region on the chromosome that is unique for each of the 3 organisms. This region, which locate near the chromosome origin of replication (oriC), is called “oriC environ”. As most of the region could be deleted without affecting growth, it can be concluded that the oriC environ region does not contain genes essential for bacterial viability. On the other hand, the region is most likely responsible for the diversification of staphylococci species which enables them to successfully colonize and infect the human host.

Besides having the oriC environ region where rearrangements of the genome can take place frequently, S.haemolyticus also possess a surprisingly large number of insertion sequences (ISs). The ISs can either inactivate a gene by direct integration into the open reading frame or activate a gene by providing the gene with a potent promoter. By changing the content of the genome, the IS elements might contribute to the innate ability of the bacteria to acquire drug resistance. While 6% of the orfs found in the more virulent S.aureus are pathogenic factors, only 2% of those found in S.haemolyticus are pathogenic factors. However, it is the ability of S.haemolyticus to alter its genome content and to acquire resistance to antibotics that makes the species a remarkable and hard-to-control opportunity pathogen.

Cell structure and metabolism

Cell Wall

(Billot-Klein,Gutmann, et al, 1996)

As a gram-positive species like other staphylococci, S.haemolyticus has a thick peptidoglycan wall outside of its membrane and therefore can be targeted by antibiotics that interfere with the peptidoglycan biosynthesis process. However, some strains of S.haemolyticus have developed resistance to glycopeptide antibiotics such as teicoplanin and vancomycin. This is an ability that is unique among staphylococci. The peptidoglycan structure of S.haemolyticus has been studied to find out the factors responsible to this special resistance.

Like that of other staphylococci, the peptidoglycan of S.haemolyticus is highly cross-linked. The predominant cross bridges are COOH-Gly-Gly-Ser-Gly-Gly-NH2 and COOH-Ala-Gly-Ser-Gly-Gly-NH2. In the resistant strains, studies have found cross bridges that contain an additional serine in place of glycine (so the probable cross bridges structures are COOH-Gly-Ser-Ser-Gly-Gly-NH2 and COOH-Ala-Gly-Ser-Ser-Gly-NH2). Furthermore, the presense of a novel cystoplasmic peptidoglycan precursor, UDP-muramyl-tetrapeptide-D-lactate, has been detected in strains of S.haemolyticus. This precursor and the alterations of cross bridges are believed to interfere with the cooperative binding of glycopeptide antibiotics like vancomycin and teicoplanin to their targets in S.haemolyticus.

Metabolism

Whole-genome sequencing of S.haemolyticus (strain JCSC1435) revealed some orfs encoding metabolic genes unique to the species, such as those involved in transport of ribose and ribitol or biosynthesis of essential components of nucleic acids and cell wall techoic acids. Thanks to these unique orfs, S.haemolyticus has a relative great biosynthetic capacity. Strain JCSC1435 only requires arginine for growth, while the S.aureus strain N315 requires the availability of many different amino acids: alanine, glycine, isoleucine, arginine, valine and proline. (Takeuchi,Watanabe, et al, 2005)

S.haemolyticus (strain JCSC1435) also possesses the ability to ferment mannitol, a metabolic character also found in some other “non-aureus” staphylococci (Takeuchi,Watanabe, et al, 2005) However, genetic analysis suggested that certain strains of S.haemolyticus might have gained this ability through horizontal gene transfer of the mannitol PTS locus from other bacterial species (Takeuchi,Watanabe, et al, 2005). Again, this can also be considered another example demonstrating the flexibility of S.haemolyticus genome.

Ecology

Staphylococcus haemolyticus can be found on the skins and in the bodies of a wide range of mammals, including prosimians, monkeys, domestic animals, and human (Tristan,Lina, et al, 2006). The most common natural habitats of the bacteria on human are in the axillae (underarm area), in the perineum (pubic area), and in the inguinal area (Tristan,Lina, et al, 2006). S.haemolyticus survive successfully on the drier regions of the body (Tristan,Lina, et al, 2006), while it can also be found frequently in human blood cultures (Takeuchi,Watanabe, et al, 2005).

It has been known that S.haemolyticus produces gonococcal growth inhibitor, GGI. The substance was first discovered to cause cytoplasmic leakage in gonococcal cells and eventually lead to cell death (Tristan,Lina, et al, 2006). Remarkably, this substance can also lyse erythrocytes, especially those of horse and human (Watson,Yaguchi, et al, 1988).

Pathology

Staphylococci in general cause disease through their ability to spread widely in tissues ad their production of extracellular substances (Brooks,Butel and Morse, 2001). One example of such substances is coagulase, an enzyme-like protein produced by S.aureus that may deposit fibrin on the surface of the bacteria, altering their ingestion and destruction by phagocytic cells (Brooks,Butel and Morse, 2001).

Traditionally, production of coagulase is considered to represent the invasive pathogenic potential among staphylococci. (Brooks,Butel and Morse, 2001) S.haemolyticus, however, is a coagulase-negative species. Therefore, like other non-aureus staphylococci, its pathogenic characters were not well-studied until recently, as S.haemolyticus is emerging to be a major cause of nosocomial infections (infections acquired during treatment at a hospital for another disease). Reported cases of infections caused by S.haemolyticus include septicemia (dysfunction of organ systems resulting from immune response to a severe infection), peritonitis (inflammation of the serous membrane lining abdominal cavity), and infections of urinary tract, wound, bone and joints. (Tristan,Lina, et al, 2006) In rare cases, S.haemolyticus has also been reported to cause infective endocarditis, inflammation of the inner of the heart (the endocardium), which might lead to severe complications such as heart failure or death. (Falcone,Campanile, et al, 2007) Common clinical symptoms of S.haemolyticus are fever and an increase in white blood cell population (leukocytosis) (Falcone,Campanile, et al, 2007).

Being the most common pathogen among staphylococci, virulent factors of S.aureus have been well-known. Important among them are different classes of enterotoxin (toxins released in lower-intestine, causing food poisoning), toxic shock syndrome toxin, and hemolysin (substances allow the bacteria to break down red-blood cells) (Novick, 2006). Some of these substances used to be considered to belong exclusively to S.aureus, but are now discovered in the other non-aureus, coagulast-negative staphylococci as well (Tristan,Lina, et al, 2006). In one studies published in 1994, all strains of S.haemolyticus under investigation produced hemolysins in vitro (Molnar,Hevessy, et al, 1994). Investigators therefore suggested that hemolysins might be the important factor responsible for the high virulence of this staphylococcus species.

S.haemolyticus’ GGI are related in function and some properties to other relative staphylococci virulent factor, such as delta-lysin in S.aureus and SLUSH (Staphylococcus lugdunensis synergistic hemolysin) in S.lugdunensis, the latter of which shows significant similarities in structure with GGI. (Tristan,Lina, et al, 2006) These findings suggest a connection between pathogenesis pathways and virulent factors of common staphylococcal pathogens.

Application to Biotechnology

Does this organism produce any useful compounds or enzymes? What are they and how are they used?

Current Research

Enter summaries of the most recent research here--at least three required

References

1. Brooks, G., Butel, J. & Morse, S. in Medical Microbiology 197-202 (McGraw-Hill, New York, 2001).

2. Falcone, M. et al. Staphylococcus haemolyticus endocarditis: clinical and microbiologic analysis of 4 cases. Diagn. Microbiol. Infect. Dis. 57, 325-331 (2007).

3. Takeuchi, F. et al. Whole-genome sequencing of staphylococcus haemolyticus uncovers the extreme plasticity of its genome and the evolution of human-colonizing staphylococcal species. J. Bacteriol. 187, 7292-7308 (2005).

4. Froggatt, J. W., Johnston, J. L., Galetto, D. W. & Archer, G. L. Antimicrobial resistance in nosocomial isolates of Staphylococcus haemolyticus. Antimicrob. Agents Chemother. 33, 460-466 (1989).

5. Billot-Klein, D. et al. Peptidoglycan synthesis and structure in Staphylococcus haemolyticus expressing increasing levels of resistance to glycopeptide antibiotics. J. Bacteriol. 178, 4696-4703 (1996).


Edited by Bao D. Truong, student of Rachel Larsen